passiv
therapi
neutral
human
monoclon
antibodi
mab
could
effect
therapi
sever
acut
respiratori
syndrom
coronaviru
sarscov
util
human
immunoglobulin
transgen
mous
produc
fulli
human
sarscov
spike
protein
specif
antibodi
antibodi
examin
reactiv
recombin
protein
antibodi
react
twentyseven
antibodi
neutral
sarscov
urbani
addit
neutral
antibodi
found
like
specif
map
bind
region
achiev
sever
recombin
protein
reactiv
neutral
mab
bound
rbd
aa
howev
two
specif
mab
react
domain
upstream
rbd
aa
immunoglobulin
gene
sequenc
analys
suggest
least
differ
bind
specif
uniqu
human
mab
could
use
cocktail
would
simultan
target
sever
neutral
epitop
prevent
emerg
escap
mutant
coronavirus
cov
histor
known
caus
rel
mild
upper
respiratori
tract
infect
account
approxim
case
common
cold
human
baker
howev
recent
identifi
cov
sever
acut
respiratori
syndrom
coronaviru
sarscov
caus
sever
respiratori
distress
human
lead
mortal
approxim
infect
individu
baker
rota
et
al
www
whointcsrsar
year
sarscov
establish
effici
human
human
transmiss
result
sever
superspread
event
end
outbreak
juli
sarscov
respons
death
case
worldwid
involv
countri
www
whointcsrsar
sinc
conclus
sar
outbreak
sever
report
confirm
case
sar
unknown
origin
indic
environment
threat
sarscov
still
exist
wwwwhoint
chines
sar
molecular
epidemiolog
consortium
sarscovlik
viru
isol
horsesho
bat
china
research
postul
natur
reservoir
viru
lau
et
al
li
et
al
sarscovlik
viru
remain
present
intermedi
wild
anim
host
himalayan
palm
civet
rais
possibl
reemerg
sarscov
infect
human
chan
et
al
peiri
yuen
linger
threat
prudent
develop
effect
modal
preand
postexposur
treatment
sarscov
infect
sar
outbreak
although
isol
measur
prove
effect
bring
outbreak
control
target
effect
treatment
sarscov
remain
highli
desir
human
sarscov
peak
viral
load
reach
approxim
day
post
onset
symptom
thu
offer
opportun
effect
postexposur
treatment
chen
et
al
chen
et
al
one
modal
treatment
may
limit
viru
replic
thu
spread
viru
passiv
immun
preform
neutral
human
monoclon
antibodi
mab
treatment
prodrom
phase
diseas
could
aid
rapid
clearanc
viru
limit
poor
clinic
outcom
person
person
spread
without
advers
effect
associ
use
corticosteroid
anim
sera
human
sera
sarscov
mediat
infect
target
cell
via
spike
protein
express
surfac
sarscov
protein
type
one
transmembran
glycoprotein
divid
two
function
domain
aa
aa
et
al
li
et
al
domain
mediat
interact
protein
cellular
receptor
angiotensinconvert
enzym
li
et
al
region
consist
amino
acid
form
receptor
bind
domain
rbd
respons
bind
recent
receptor
bind
motif
rbm
within
rbd
consist
amino
acid
shown
directli
contact
tip
li
et
al
domain
protein
contribut
infect
target
cell
mediat
fusion
viral
host
membran
conform
chang
two
conserv
helic
region
protein
brought
togeth
form
sixhelix
bundl
fusion
core
et
al
huang
et
al
ingallinella
et
al
tripet
et
al
therapi
disrupt
interact
domain
viru
receptor
like
confer
protect
therapeut
valu
protein
serv
main
antigen
elicit
protect
immun
respons
includ
neutral
antibodi
infect
human
anim
bisht
et
al
buchholz
et
al
chen
et
al
greenough
et
al
et
al
hofmann
et
al
intranas
intramuscular
applic
modifi
vaccinia
viru
ankara
mva
express
protein
mice
elicit
sarscov
neutral
antibodi
bisht
et
al
immun
mice
dna
vaccin
encod
sequenc
devoid
cytoplasm
domain
andor
transmembran
domain
result
develop
neutral
antibodi
well
cell
respons
howev
humor
igg
compon
immun
cellular
compon
inhibit
viral
replic
fact
transfer
immun
serum
immun
mice
naiv
mice
reduc
sarscov
titer
follow
viral
challeng
togeth
studi
demonstr
primarili
ab
respons
protect
sarscov
replic
indic
potenti
therapeut
valu
passiv
transfer
neutral
ab
sarscov
immunogen
properti
protein
includ
abil
induc
neutral
antibodi
essenti
role
viral
attach
fusion
make
ideal
target
develop
effect
immunotherapi
sarscov
infect
passiv
therapi
human
immunoglobulin
confer
immedi
protect
without
deleteri
effect
associ
use
anim
chimer
ab
contain
anim
deriv
amino
acid
sequenc
lonberg
sever
way
produc
human
mab
method
use
take
advantag
transgen
amgen
british
columbia
inc
burnabi
bc
mous
immunoglobulin
ig
gene
replac
gene
encod
human
ig
unlik
use
human
b
cell
infect
immun
individu
anim
allow
repeat
immun
antigen
choic
induc
b
cell
capabl
produc
wide
array
function
relev
mab
high
affin
antigen
without
antibodi
engin
rathanaswami
et
al
approach
highli
flexibl
allow
extens
screen
select
differ
antibodi
uniqu
properti
furthermor
human
mab
directli
produc
hybridoma
ig
gene
clone
use
gener
recombin
cell
line
necessari
advantag
use
produc
larg
panel
neutral
human
mab
sarscov
protein
distinct
specif
anim
immun
ectodomain
protein
hybridoma
produc
standard
protocol
davi
et
al
initi
hybridoma
grown
exhaust
supernat
test
recombin
protein
counterscreen
protein
control
larg
primari
screen
follow
addit
secondari
screen
result
identif
hybridoma
capabl
produc
human
antibodi
ab
specif
sarscov
protein
minimum
od
valu
tabl
ab
show
wide
rang
bind
effici
determin
elisa
mani
yield
satur
od
valu
greater
tabl
initi
screen
highest
react
ab
select
test
character
ab
examin
reactiv
domain
protein
urbani
contain
aa
screen
identifi
ab
specif
domain
protein
reactiv
rang
fig
sampl
od
valu
greater
averag
background
valu
consid
posit
fig
human
ab
deriv
effect
neutral
sarscov
urbani
protein
reactiv
ab
test
abil
neutral
sarscov
microneutr
assay
twentyseven
strongli
reactiv
ab
show
complet
neutral
tabl
mention
immun
full
ectodomain
protein
though
analysi
focus
reactiv
ab
remain
nonreact
ab
examin
microneutr
assay
addit
ab
found
complet
neutral
sarscov
urbani
data
shown
addit
three
ab
react
domain
examin
microneutr
assay
howev
neutral
sarscov
data
shown
differenti
reactiv
hybridoma
supernat
fragment
suggest
sever
differ
region
protein
recogn
human
antibodi
deriv
recombin
protein
human
fc
tag
produc
cell
purifi
examin
differenti
bind
target
region
reactiv
ab
fig
react
ab
analyz
reactiv
addit
protein
fragment
elisa
ie
fig
smallest
fragment
encod
minim
rbd
often
fig
reactiv
hmab
produc
hybridoma
gener
immun
fragment
elisa
reactiv
ab
test
coat
recombin
protein
ab
react
test
reactiv
three
fragment
yield
highest
reactiv
ab
test
rel
fragment
often
demonstr
least
reactiv
suggest
region
could
partial
mask
epitop
within
fragment
fig
antibodi
yield
od
valu
ab
yield
approxim
background
group
base
reactiv
variou
fragment
tabl
comparison
ab
reactiv
across
fragment
indic
ab
react
within
rbd
ab
bound
fell
four
group
group
design
base
differenti
reactiv
fragment
tabl
fragment
contain
possibl
mask
domin
epitop
repres
high
number
ab
found
group
yield
high
od
valu
fragment
contain
region
differ
fragment
reactiv
suggest
epitop
recogn
ab
group
react
andor
fragment
lack
reactiv
fragment
contain
aa
differ
group
react
fragment
contain
region
though
group
ab
appear
bind
within
epitop
map
attempt
use
overlap
peptid
deriv
region
domain
provid
nih
peptid
consist
amino
acid
amino
acid
overlap
none
ab
show
signific
reactiv
peptid
indic
antibodi
recogn
either
conform
epitop
andor
requir
glycosyl
thirtythre
ab
found
like
react
ie
group
ab
react
howev
react
group
addit
react
suggest
ab
recogn
epitop
within
region
addit
ab
found
react
tail
region
recombin
protein
like
bind
ab
react
sole
fragment
includ
tail
region
ab
group
vari
reactiv
fragment
relev
group
suggest
ab
recogn
differ
epitop
vari
affin
affect
presenc
group
compar
lack
aa
group
compar
group
react
tabl
mice
immun
fulllength
protein
therefor
ab
react
domain
examin
reactiv
domain
region
none
antibodi
react
three
show
signific
reactiv
two
three
bind
ab
result
high
od
valu
data
shown
human
ab
recogn
differ
region
vari
neutral
potenti
signific
proport
reactiv
neutral
ab
react
rbd
consist
result
obtain
group
examin
neutral
ab
sarscov
greenough
et
al
et
al
b
et
al
subbarao
et
al
major
neutral
ab
fell
group
suggest
two
group
recogn
domin
neutral
epitop
contrari
ab
fall
group
appear
recogn
signific
neutral
epitop
sinc
neutral
ab
identifi
group
tabl
three
addit
neutral
ab
found
like
bind
region
amino
acid
domain
analog
studi
shown
neutral
abil
ab
bind
upstream
known
rbd
ie
greenough
et
al
antibodi
direct
import
neutral
epitop
account
approxim
total
specif
ab
gener
therefor
major
ab
appear
recogn
nonneutr
epitop
within
tabl
purif
character
neutral
human
monoclon
antibodi
mab
hybridoma
neutral
mab
clone
limit
dilut
confirm
ig
gene
sequenc
twentyfour
previous
identifi
neutral
antibodi
recov
purifi
protein
ag
affin
column
subsequ
confirm
monoclon
ig
gene
sequenc
follow
purif
reactiv
mab
retest
fragment
fail
bind
high
elisa
reactiv
relev
fragment
note
initi
screen
maintain
purif
mab
fig
mab
demonstr
dose
depend
bind
od
valu
decreas
increas
dilut
antibodi
mab
maintain
high
od
valu
possibl
indic
rel
higher
affin
howev
overal
bind
somewhat
lower
mab
higher
concentr
possibl
reflect
avail
epitop
fig
increas
dilut
purifi
mab
test
abil
neutral
sarscov
urbani
neutral
titer
antibodi
defin
lowest
concentr
mab
capabl
complet
neutral
sarscov
mab
vari
neutral
potenti
mab
neutral
sarscov
concentr
low
howev
mab
abl
neutral
viru
concentr
tabl
varianc
neutral
abil
mab
may
due
differ
affin
fine
bind
specif
andor
extent
avail
target
epitop
viral
express
nativ
protein
often
degre
reactiv
elisa
correl
neutral
titer
fig
tabl
suggest
possibl
limit
avail
relev
epitop
viral
express
nativ
protein
rel
avail
particular
recombin
fragment
thu
limit
neutral
abil
certain
mab
immunoglobulin
ig
gene
sequenc
suggest
differ
bind
specif
among
human
mab
purifi
mab
sequenc
previou
group
design
divid
base
immunoglobulin
gene
sequenc
data
sequenc
analysi
suggest
least
differ
bind
specif
among
panel
mab
uniqu
bind
specif
deduc
usag
differ
v
j
gene
sequenc
case
heavi
chain
h
chain
preferenti
usag
rearrang
light
chain
l
chain
mab
use
rearrang
l
chain
v
region
use
time
pair
differ
j
segment
less
repetit
h
chain
rearrang
though
preferenti
usag
rearrang
h
chain
use
time
rearrang
l
chain
next
frequent
h
chain
rearrang
also
pair
rearrang
l
chain
addit
sever
uniqu
rearrang
h
chain
usual
pair
uniqu
rearrang
l
chain
tabl
analysi
allow
group
establish
earlier
elisa
reactiv
subdivid
base
assumpt
differ
gene
rearrang
constitut
product
uniqu
bind
site
therefor
exampl
group
divid
like
differ
specif
base
differ
v
j
usag
h
l
chain
tabl
first
group
h
chain
rearrang
pair
l
chain
though
group
also
use
rearrang
l
chain
h
chain
rearrang
differ
like
result
recognit
differ
epitop
group
tabl
remain
member
group
uniqu
h
l
chain
rearrang
like
recogn
uniqu
epitop
tabl
differ
h
chain
l
chain
rearrang
import
influenc
structur
region
confer
bind
specif
differ
rearrang
result
differ
region
sequenc
h
l
chain
fig
tabl
data
demonstr
sequenc
differ
within
region
sever
mab
region
group
except
fourth
posit
h
chain
group
rather
germlin
encod
group
fig
tabl
chang
alter
bind
specif
affin
two
group
mab
therefor
specif
identif
recogn
epitop
requir
delin
differ
group
mab
two
group
mab
show
chang
region
exampl
three
amino
acid
differ
within
compar
although
fall
group
v
j
usag
fig
mab
singl
amino
acid
chang
region
compar
chang
may
alter
affin
bind
region
within
protein
result
slightli
better
neutral
abil
note
fig
addit
sever
mab
chang
one
four
framework
region
make
structur
mab
data
shown
though
cdr
region
form
antigen
bind
pocket
chang
within
framework
region
also
contribut
bind
specif
affin
therefor
chang
could
result
greater
separ
mab
group
base
cdr
region
result
differ
specif
protein
bind
affin
region
exampl
belong
group
howev
carri
mutat
framework
region
could
potenti
alter
recognit
protein
mab
therefor
set
apart
member
group
monoclon
ab
belong
group
howev
singl
amino
acid
chang
framework
region
may
influenc
bind
specif
affin
therefor
influenc
neutral
capabl
data
shown
consist
find
group
shown
immun
recombin
protein
result
product
sarscov
specif
neutral
ab
berri
et
al
bisht
et
al
buchholz
et
al
greenough
et
al
et
al
et
al
hofmann
et
al
moreov
abl
use
b
cell
mice
gener
panel
neutral
human
mab
sarscov
major
reactiv
mab
react
rbd
like
neutral
viru
block
sarscov
protein
bind
li
et
al
sui
et
al
therefor
appar
mab
produc
current
studi
recogn
critic
domain
involv
induct
effect
immun
respons
sarscov
infect
also
viral
attach
et
al
et
al
b
ig
sequenc
analysi
indic
preferenti
usag
certain
h
l
chain
gene
name
sever
mab
react
fragment
exhibit
consider
divers
h
l
chain
gene
segment
usag
suggest
mab
possibl
recogn
distinct
epitop
within
given
domain
major
neutral
mab
bound
fell
group
exhibit
similar
fragment
bind
pattern
howev
ig
sequenc
data
suggest
could
differ
bind
specif
within
two
group
exampl
group
whose
like
bind
region
could
divid
differ
bind
specif
base
differ
v
j
rearrang
yield
uniqu
region
addit
variat
seen
within
sequenc
mab
common
ig
gene
usag
seen
group
suggest
mab
may
bind
differ
epitop
bind
rbd
epitop
vari
affin
base
upon
ig
sequenc
analysi
specul
least
differ
bind
specif
may
repres
panel
mab
consid
mutat
found
framework
region
could
increas
number
differ
specif
contribut
framework
region
ab
bind
illustr
gener
chimer
antibodi
respiratori
syncyti
viru
rsv
cdr
region
neutral
murin
mab
transfer
tabl
summari
hmab
reactiv
neutral
titer
heavi
h
light
l
chain
usag
hmab
group
reactiv
framework
region
human
result
chimer
mab
lost
repres
neutral
abil
tempest
et
al
tempest
et
al
therefor
potenti
chang
saw
cdr
framework
region
sar
specif
mab
may
result
differ
bind
specif
affin
howev
detail
epitop
map
requir
fulli
character
fine
bind
specif
mab
addit
antibodi
bind
rbd
isol
neutral
mab
group
interact
epitop
contain
within
amino
acid
upstream
rbd
presenc
neutral
epitop
demonstr
import
yet
unclearli
defin
role
region
sarscov
infect
sinc
region
implic
bind
mab
may
prevent
protein
acquir
conform
requir
mediat
fusion
target
membran
delet
within
first
aa
elimin
fusion
abil
protein
celltocel
fusion
assay
maintain
receptor
bind
function
xiao
et
al
ntermin
region
protein
also
seem
play
role
trimer
protein
structur
may
requir
fusion
xiao
et
al
therefor
bind
mab
region
may
interfer
import
step
facilit
fusion
function
character
mab
could
yield
inform
function
region
sarscov
protein
viral
entri
screen
fulllength
reactiv
nonreact
ab
result
identif
addit
neutral
ab
ab
like
react
junction
within
domain
recogn
import
conform
epitop
requir
entir
protein
sinc
domain
involv
fusion
viral
cellular
membran
antibodi
specif
region
within
domain
like
neutral
inhibit
fusion
antibodi
valu
care
studi
fusion
event
moreov
domain
highli
conserv
domain
therefor
region
reactiv
mab
combin
mab
distinct
bind
specif
prevent
viral
attach
creat
mixtur
antibodi
broader
rang
specif
effect
prevent
infect
wide
rang
clinic
isol
rota
et
al
zhang
et
al
addit
approach
would
significantli
reduc
elimin
possibl
gener
antigen
variant
might
readili
aris
singl
mab
use
mab
produc
studi
uniqu
express
human
heavi
light
chain
proven
therapeut
valu
antibodi
number
ad
advantag
igg
antibodi
readili
avail
extracellular
bodi
fluid
known
properti
igg
antibodi
igg
antibodi
fail
activ
classic
complement
pathway
sinc
essenti
fc
receptor
fcr
igg
macrophag
phagocyt
antibodi
bind
mediat
function
effect
unlik
facilit
antibodi
depend
enhanc
ade
viral
infect
fcr
immunogen
nonhuman
deriv
ab
chimer
ab
anim
sequenc
could
result
rapid
clearanc
reduc
efficaci
lin
et
al
addit
advers
reaction
like
seen
chimer
ab
differ
speci
could
avoid
use
human
mab
human
mab
structur
intact
thu
retain
full
complement
function
properti
outbreak
sarscov
mutat
exhibit
antigen
variat
fact
sequenc
analysi
indic
clinic
isol
could
divid
earli
middl
late
isol
sui
et
al
signific
demonstr
abil
later
isol
escap
neutral
mab
effect
neutral
earlier
isol
yang
et
al
therefor
import
produc
neutral
mab
effect
wide
rang
clinic
isol
antigen
divers
potenti
evolut
antigen
variant
effect
passiv
therapi
sarscov
like
contain
cocktail
neutral
mab
target
differ
epitop
andor
step
entri
process
block
receptor
bind
fusion
believ
sever
mab
use
prepar
cocktail
potenti
therapeut
use
addit
identifi
neutral
epitop
conserv
rang
clinic
isol
signific
implic
develop
effect
vaccin
larg
devoid
nonneutr
epitop
traggiai
et
al
antibodi
proven
import
immun
respons
sarscov
bisht
et
al
buchholz
et
al
chen
et
al
greenough
et
al
et
al
hofmann
et
al
zhang
et
al
recov
patient
show
higher
ab
titer
neutral
ab
protein
maintain
zhang
et
al
therefor
util
human
mab
viabl
therapeut
option
treatment
sarscov
infect
ab
capabl
neutral
vitro
usual
also
confer
vivo
protect
viral
challeng
reduc
viral
titer
chen
et
al
greenough
et
al
sui
et
al
sui
et
al
yang
et
al
therefor
mab
may
use
passiv
immunotherapi
provid
instantan
protect
individu
infect
sarscov
case
reemerg
sarscov
human
popul
sar
coronaviru
sarscov
urbani
strain
obtain
cdc
viru
propag
vero
cell
optipro
serum
free
medium
sfm
gibco
carlsband
ca
tcid
valu
determin
infect
vero
cellswel
well
plate
serial
dilut
sarscov
day
incub
co
humidifi
incub
cell
evalu
cytopath
effect
cpe
tcid
valu
calcul
reedmuench
method
cdna
encod
amino
acid
ectodomain
protein
kind
gift
marco
marra
carolin
astel
british
columbia
cancer
agenc
genom
scienc
centr
clone
baculodirect
tm
baculoviru
express
system
invitrogen
carlsband
ca
frame
protein
express
cell
purifi
use
probond
tm
nickelchel
resin
invitrogen
carlsband
ca
urbani
fragment
use
screen
domain
map
consist
amino
acid
addit
signal
sequenc
human
igg
fc
lack
transmembran
domain
express
plasmid
encod
differ
fragment
ie
aa
transform
ultracompet
cell
invitrogen
carlsband
ca
select
tetracyclin
ampicillin
agar
plate
construct
confirm
restrict
analysi
use
nhei
bamhi
cdna
encod
fragment
transfect
cell
use
capo
transfect
kit
invitrogen
carlsband
ca
briefli
cell
seed
day
prior
transfect
medium
chang
follow
morn
capo
transfect
procedur
perform
follow
dna
cacl
steril
h
mix
ad
dropwis
hb
aerat
valu
per
transfect
plate
next
day
cell
wash
pb
mm
cacl
mgcl
medium
replac
sfm
supplement
mm
lglutamin
antibioticantimycot
gibco
carlsband
ca
cell
incub
addit
h
time
medium
harvest
proteas
inhibitor
tablet
ad
roch
diagnost
indianapoli
supernat
spun
rpm
min
supernat
mix
proteina
sepharos
bead
santa
cruz
biotechnolog
santa
cruz
ca
rock
overnight
bead
wash
pb
cacl
mgcl
nacl
one
time
follow
two
addit
wash
pb
cacl
mgcl
protein
elut
use
mm
sodium
mm
glycin
ph
neutral
immedi
use
trishcl
ph
protein
concentr
centricon
filter
millipor
bedford
spin
rpm
h
dialyz
overnight
pb
protein
product
verifi
sdspage
follow
coomassi
blue
biorad
hercul
ca
stain
ident
protein
confirm
western
blot
use
pool
sera
obtain
mice
immun
inactiv
viru
five
microgram
purifi
protein
emulsifi
titermax
gold
adjuv
sigma
oakvil
week
old
igg
anim
immun
intraperiton
subsequ
boost
perform
sequenti
use
titermax
gold
alum
sigma
oakvil
adjuv
anim
develop
anti
antibodi
respons
final
boost
pb
perform
day
later
spleen
lymph
cell
harvest
fuse
myeloma
cell
hprt
hybridoma
select
hypoxanthineazaserin
ha
use
standard
protocol
davi
et
al
hybridoma
supernat
total
well
individu
screen
reactiv
elisa
secondari
screen
well
counter
screen
neg
control
perform
hybridoma
supernat
yield
od
valu
test
test
variou
fragment
elisa
initi
screen
carri
use
fulllength
briefli
plate
coat
ngwell
protein
overnight
plate
block
use
nonfat
milk
h
room
temperatur
wash
hybridoma
supernat
dilut
ad
well
incub
room
temperatur
h
wash
well
hrp
conjug
goatantihuman
antibodi
ad
incub
h
room
temperatur
follow
wash
antibodi
bind
detect
use
substrat
bd
opteia
bd
bioscienc
pharmigen
san
diego
ca
reaction
stop
use
hcl
absorb
read
use
micropl
reader
biorad
hercul
ca
nm
procedur
follow
screen
hybridoma
supernat
use
dilut
purifi
human
monoclon
antibodi
mab
use
fragment
neutral
abil
hybridoma
supernat
sarscov
urbani
test
use
microneutr
assay
vero
cell
seed
cell
per
well
well
plate
optipro
sfm
gibco
carlsband
ca
hour
prior
neutral
assay
neutral
abil
ab
hybridoma
supernat
test
mix
hybridoma
supernat
dilut
optipro
sfm
gibco
carlsband
ca
viru
medium
h
follow
incub
antibodyviru
mixtur
ad
duplic
vero
cell
incub
day
time
cell
visual
observ
cytopath
effect
cpe
indic
round
vero
cell
indic
sarscov
infect
assay
perform
use
serial
dilut
purifi
human
monoclon
antibodi
mab
hybridoma
posit
product
neutral
antibodi
clone
limit
dilut
clone
cultur
produc
larg
quantiti
mab
supernat
hybridoma
purifi
use
protein
ag
affin
column
total
rna
purifi
approxim
hybridoma
cell
use
rneasi
mini
kit
qiagen
mississauga
per
manufactur
instruct
pcr
amplif
protocol
primer
previous
describ
gallo
et
al
mark
et
al
v
famili
primer
pool
use
individu
sequenc
perform
lone
star
lab
houston
tx
use
termin
version
dna
sequenc
kit
appli
biosystem
foster
citi
ca
abi
autom
sequenc
appli
biosystem
foster
citi
ca
